Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.43 |
| ▸ | ITK | Q08881 | 5/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.41 |
| ▸ | MERTK | Q12866 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447857 | 1.00 | EGFR (0.43) | EGFRITKTYRO3MERTKSYK | |
| SCHEMBL3447855 | 1.00 | EGFR (0.43) | EGFRITKTYRO3MERTKSYK | |
| SCHEMBL13312590 | 1.00 | EGFR (0.43) | EGFRITKTYRO3MERTKSYK | |
| SCHEMBL3449272 | 1.00 | EGFR (0.43) | EGFRITKTYRO3MERTKSYK | |
| SCHEMBL13312565 | 0.90 | EGFR (0.41) | EGFRITKTYRO3MERTKAXL | |
| SCHEMBL13310976 | 0.90 | EGFR (0.41) | EGFRITKTYRO3MERTKAXL | |
| SCHEMBL3450783 | 0.90 | EGFR (0.41) | EGFRITKTYRO3MERTKAXL | |
| SCHEMBL3450789 | 0.87 | EGFR (0.41) | EGFRITKTYRO3MERTKSYK | |
| SCHEMBL3450787 | 0.87 | EGFR (0.41) | EGFRITKTYRO3MERTKSYK | |
| SCHEMBL3450057 | 0.87 | IRAK4 (0.42) | EGFRITKTYRO3MERTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | EGFR 2771/4885ITK 2005/4885TYRO3 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.